P4817 12/04

DESCRIPTION

Each soft gelatin capsule for oral administration contains:

Iron

   Ferrochel® * (elemental iron) ................................ 70 mg

   Ferrous fumerate (elemental iron) .......................... 81 mg

Vitamin C as Ester-C®

   Ascorbic acid (as calcium ascorbate) .................... 60 mg

   Threonic acid (as calcium threonate) .................... 0.8 mg

Folic Acid, USP ...................................................... 1 mg

Vitamin B 12 (cyanocobalamin) .............................. 10 mcg

* Ferrochel® (ferrous bis-glycinate chelate) is a registered trademark of Albion International, Inc., Clearfield, Utah, and is protected under U.S. Patent Nos. 4,599,152 and 4,830,716.
Ester-C® is a patented pharmaceutical grade material consisting of calcium ascorbate and calcium threonate. Ester-C® is a licensed trademark of Zila Nutraceuticals, Inc.

Inactive Ingredients:    Soybean oil, gelatin, glycerine, lecithin (unbleached), yellow beeswax, titanium dioxide, methyl paraben, ethyl vanillin, FD& Yellow No. 6, FD&Red No. 40, propyl paraben, FD& Blue No. 1.

INDICATIONS AND USAGE

For the treatment of all anemias responsive to oral iron therapy, such as hypochromic anemia associated with pregnancy, chronic or acute blood loss, dietary restriction, metabolic disease and post-surgical convalescence.

CONTRAINDICATIONS

This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Hemochromatosis and hemosiderosis are contraindications to iron therapy.

WARNINGS

Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B 12 is deficient.

WARNING:    Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

Allergy Alert: These gelatin capsules contain a soy product.

PRECAUTIONS

General

Do not exceed recommended dose.

Folic Acid

Folic acid in doses above 1.0 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. Pernicious anemia should be excluded before using this product since folic acid may mask the symptoms of pernicious anemia.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

Clinical studies on this product have not been performed in sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

ADVERSE REACTIONS

Adverse reactions with iron therapy may include constipation, diarrhea, nausea, vomiting, dark stools and abdominal pain. Adverse reactions with iron therapy are usually transient.

Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

DOSAGE AND ADMINISTRATION

Usual adult dose is 1 to 2 soft gelatin capsules daily, or as directed by a physician.

HOW SUPPLIED

Chromagen® Forte Capsules are brown soft gelatin capsules imprinted with "THX 0131" in grey ink in child- resistant, unit-dose packages of 100 capsules (10 x 10 Unit Dose Packs) (NDC 64011-131-11).

Store at controlled room temperature 25°C (77°F); excursions permitted to 15°- 30°C (59°- 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat 40°C (104°F). Avoid freezing.

Mktd. by Ther-Rx Corp.

St. Louis, MO 63044

U.S. Patent Nos. 4,599,152; 4,822,816; 4,830,716; 5,070,085.

P4817 12/04

PRODUCT PHOTO(S):

NOTE: These photos can be used only for identification by shape, color, and imprint. They do not depict actual or relative size.

The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a quick-reference identification aid. While every effort has been made to assure accurate reproduction, please remember that any visual identification should be considered preliminary. In cases of poisoning or suspected overdosage, the drug's identity should be verified by chemical analysis.

images/pills/p06335c7.jpg



Copyright© 2006 Thomson PDR